An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 12 Sep 2017 Results (n=458) presented at the 42nd European Society for Medical Oncology Congress
- 31 Aug 2017 According to an Eisai Inc media release, the company will present the new clinical data from this trial at European Society of Medical Oncology (ESMO) 2017.
- 03 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2019.